148 related articles for article (PubMed ID: 11477444)
21. Therapeutic drug monitoring of intravenous busulfan in Thai children undergoing hematopoietic stem cell transplantation: A pilot study.
Jansing T; Sanpakit K; Tharnpanich T; Jiranantakan T; Niphandwongkorn V; Chindavijak B; Suansanae T
Pediatr Hematol Oncol; 2021 May; 38(4):346-357. PubMed ID: 33656974
[TBL] [Abstract][Full Text] [Related]
22. Targeted-dose of busulfan: Higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 µMol⸱min. A historically controlled clinical trial.
Esteves I; Santos FPS; Ribeiro AAF; Seber A; Sugawara EK; Sobrinho JJDN; Barros JC; Oliveira JSR; Fernandes JF; Hamerschlak N; Andersson BS; de Lima M; Kerbauy FR
Hematol Oncol; 2020 Dec; 38(5):773-781. PubMed ID: 32779746
[TBL] [Abstract][Full Text] [Related]
23. Personalized pharmacokinetic targeting with busulfan in allogeneic hematopoietic stem cell transplantation in infants with acute lymphoblastic leukemia.
Takachi T; Arakawa Y; Nakamura H; Watanabe T; Aoki Y; Ohshima J; Takahashi Y; Hirayama M; Miyamura T; Sugita K; Koh K; Horibe K; Ishii E; Mizutani S; Tomizawa D
Int J Hematol; 2019 Sep; 110(3):355-363. PubMed ID: 31201644
[TBL] [Abstract][Full Text] [Related]
24. Monitoring of Busulphan Concentrations in Children Undergone Hematopoietic Stem Cell Transplantation: Unicentric Experience over 10 years.
Faraci M; Tinelli C; Lanino E; Giardino S; Leoni M; Ferretti M; Castagnola E; Broglia M; De Silvestri A; Di Martino D; Bartoli A
Eur J Drug Metab Pharmacokinet; 2018 Apr; 43(2):173-181. PubMed ID: 28801891
[TBL] [Abstract][Full Text] [Related]
25. The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation.
Uppugunduri CR; Rezgui MA; Diaz PH; Tyagi AK; Rousseau J; Daali Y; Duval M; Bittencourt H; Krajinovic M; Ansari M
Pharmacogenomics J; 2014 Jun; 14(3):263-71. PubMed ID: 24165757
[TBL] [Abstract][Full Text] [Related]
26. Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach?
Brooks KM; Jarosinski P; Hughes T; Kang E; Shah NN; Gall JBL; Hickstein DD; De Ravin SS; George JM; Kumar P
J Clin Pharmacol; 2018 Mar; 58(3):332-339. PubMed ID: 29238995
[TBL] [Abstract][Full Text] [Related]
27. Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning.
Zao JH; Schechter T; Liu WJ; Gerges S; Gassas A; Egeler RM; Grunebaum E; Dupuis LL
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1471-8. PubMed ID: 25977229
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic Drug Monitoring of Busulfan for the Management of Pediatric Patients: Cross-Validation of Methods and Long-Term Performance.
Choong E; Uppugunduri CRS; Marino D; Kuntzinger M; Doffey-Lazeyras F; Lo Piccolo R; Chalandon Y; Peters C; Daali Y; Ansari M
Ther Drug Monit; 2018 Feb; 40(1):84-92. PubMed ID: 29189665
[TBL] [Abstract][Full Text] [Related]
29. Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning.
Bremer S; Fløisand Y; Brinch L; Gedde-Dahl T; Bergan S
Ther Drug Monit; 2015 Aug; 37(4):493-500. PubMed ID: 25565670
[TBL] [Abstract][Full Text] [Related]
30. Maternal Administration of Busulfan before in Utero Hematopoietic Cell Transplantation Improves Congenic Bone Marrow Cell Engraftment in a Murine Model.
Shi C; Li Z; Sun Z; Pan L
Transplant Cell Ther; 2024 Apr; 30(4):398.e1-398.e10. PubMed ID: 38331194
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and Pharmacodynamics of Treosulfan in Patients With Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Mohanan E; Panetta JC; Lakshmi KM; Edison ES; Korula A; Na F; Abraham A; Viswabandya A; George B; Mathews V; Srivastava A; Balasubramanian P
Clin Pharmacol Ther; 2018 Sep; 104(3):575-583. PubMed ID: 29247522
[TBL] [Abstract][Full Text] [Related]
32. New dosing nomogram and population pharmacokinetic model for young and very young children receiving busulfan for hematopoietic stem cell transplantation conditioning.
Poinsignon V; Faivre L; Nguyen L; Neven B; Broutin S; Moshous D; Bourget P; Dufour C; Dalle JH; Galambrun C; Devictor B; Kemmel V; De Berranger E; Gandemer V; Vannier JP; Jubert C; Bondu S; Mir O; Petain A; Vassal G; Paci A
Pediatr Blood Cancer; 2020 Oct; 67(10):e28603. PubMed ID: 32706505
[TBL] [Abstract][Full Text] [Related]
33. Busulfan Pharmacokinetics in Adenosine Deaminase-Deficient Severe Combined Immunodeficiency Gene Therapy.
Bradford KL; Liu S; Krajinovic M; Ansari M; Garabedian E; Tse J; Wang X; Shaw KL; Gaspar HB; Candotti F; Kohn DB
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1819-1827. PubMed ID: 32653625
[TBL] [Abstract][Full Text] [Related]
34. Targeted Busulfan therapy with a steady-state concentration of 600-700 ng/mL in patients with sickle cell disease receiving HLA-identical sibling bone marrow transplant.
Maheshwari S; Kassim A; Yeh RF; Domm J; Calder C; Evans M; Manes B; Bruce K; Brown V; Ho R; Frangoul H; Yang E
Bone Marrow Transplant; 2014 Mar; 49(3):366-9. PubMed ID: 24317124
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics analysis results are similar for oral compared to intravenous busulfan in patients undergoing hematopoietic stem cell transplantation, except for the earlier onset of mucositis. A controlled clinical study.
Esteves I; Santos FPS; Fernandes JF; Seber A; Oliveira JSR; Hamerschlak N; Kerbauy FR; S Andersson B; de Lima M
Bone Marrow Transplant; 2019 Nov; 54(11):1799-1804. PubMed ID: 31089278
[TBL] [Abstract][Full Text] [Related]
36. Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patients.
Ansari M; Huezo-Diaz P; Rezgui MA; Marktel S; Duval M; Bittencourt H; Cappelli B; Krajinovic M
Bone Marrow Transplant; 2016 Mar; 51(3):377-83. PubMed ID: 26691424
[TBL] [Abstract][Full Text] [Related]
37. Metabolic Syndrome and Cardiovascular Risk Factors after Hematopoietic Cell Transplantation in Severe Mucopolysaccharidosis Type I (Hurler Syndrome).
Braunlin E; Steinberger J; DeFor T; Orchard P; Kelly AS
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1289-1293. PubMed ID: 29409846
[TBL] [Abstract][Full Text] [Related]
38. Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration-time curve in pediatric hematopoietic stem cell transplant recipients.
Watanabe E; Nishikawa T; Ikawa K; Yamaguchi H; Abematsu T; Nakagawa S; Kurauchi K; Kodama Y; Tanabe T; Shinkoda Y; Matsumoto K; Okamoto Y; Takeda Y; Kawano Y
Int J Hematol; 2015 Nov; 102(5):611-6. PubMed ID: 26243625
[TBL] [Abstract][Full Text] [Related]
39. Dosing algorithm revisit for busulfan following IV infusion.
Wang Y; Kato K; Le Gallo C; Armstrong E; Rock E; Wang X
Cancer Chemother Pharmacol; 2015 Mar; 75(3):505-12. PubMed ID: 25561350
[TBL] [Abstract][Full Text] [Related]
40. Once-daily i.v. BU-based conditioning regimen before allogeneic hematopoietic SCT: a study of influence of GST gene polymorphisms on BU pharmacokinetics and clinical outcomes in Chinese patients.
Yin J; Xiao Y; Zheng H; Zhang YC
Bone Marrow Transplant; 2015 May; 50(5):696-705. PubMed ID: 25730183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
